EC 3.1.4.17 - 3',5'- cyclic- nucleotide 5'- nucleotidohydrolase (3',5'- cyclic- nucleotide phosphodiesterase)

3D structures of EC 3.1.4.17 - 3',5'-cyclic-nucleotide phosphodiesterase in Protein Data Bank

updated: 6 January 2022, 2:15

1. 1f0j: Catalytic Domain of Human Phosphodiesterase 4B2B
2. 1ksg: Complex of Arl2 and Pde Delta, Crystal Form 1
3. 1ksh: Complex of Arl2 and Pde Delta, Crystal Form 2 (native)
4. 1ksj: Complex of Arl2 and Pde Delta, Crystal Form 2 (semet)
5. 1loi: N-terminal Splice Region of Rat C-amp Phosphodiesterase, Nmr, 7 Structures
6. 1mkd: Crystal Structure of PDE4D Catalytic Domain and Zardaverine Complex
7. 3ly2: Catalytic Domain of Human Phosphodiesterase 4b in Complex with a Coumarin-based Inhibitor
8. 3lxg: Crystal Structure of Rat Phosphodiesterase 10a in Complex with Ligand Web-3
9. 3kkt: Crystal Structure of Human PDE4B with 5-[3-[(1s,2s,4r)- Bicyclo[2.2.1]hept-2-yloxy]-4-methoxyp Henyl]tetrahydro- 2(1h)-pyrimidinone Reveals Ordering of The C-terminal Helix Residues 502-509.
10. 3k4s: The Structure of The Catalytic Domain of Human PDE4D with 4- (3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone
11. 1oyn: Crystal Structure of PDE4D2 in Complex with (r,s)-rolipram
12. 3jwr: Crystal Structure of Chimeric Pde5/pde6 Catalytic Domain Complexed with 3-isobutyl-1-methylxanthine (ibmx) and Pde6 Gamma-subunit Inhibitory Peptide 70-87.
13. 3itu: HPDE2A Catalytic Domain Complexed with Ibmx
14. 3itm: Catalytic Domain of HPDE2A
15. 3ibj: X-ray Structure of PDE2A
16. 3ib8: Crystal Structure of Full Length Rv0805 in Complex with 5'- Amp
17. 3ib7: Crystal Structure of Full Length Rv0805
18. 1ptw: The Crystal Structure of Amp-bound Pde4 Suggests a Mechanism for Phosphodiesterase Catalysis
19. 3iak: Crystal Structure of Human Phosphodiesterase 4d (PDE4D) with Papaverine.
20. 3iad: Crystal Structure of Human Phosphodiesterase 4d with Bound Allosteric Modulator
21. 3i8v: Crystal Structure of Human PDE4A with 4-(3-butoxy-4- Methoxyphenyl)methyl-2-imidazolidone
22. 1q9m: Three Dimensional Structures of PDE4D in Complex with Roliprams and Implication on Inhibitor Selectivity
23. 3hr1: Discovery of Novel Inhibitors of PDE10A
24. 3hqz: Discovery of Novel Inhibitors of PDE10A
25. 3hqy: Discovery of Novel Inhibitors of PDE10A
26. 3hqw: Discovery of Novel Inhibitors of PDE10A
27. 3hmv: Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with a Tetrahydrobenzothiophene Inhibitor
28. 3gwt: Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with a Quinoline Inhibitor
29. 1rkp: Crystal Structure of PDE5A1-IBMX
30. 1ro6: Crystal Structure of PDE4B2B Complexed with Rolipram (r & S)
31. 1ro9: Crystal Structures of The Catalytic Domain of Phosphodiesterase 4B2B Complexed with 8-br-amp
32. 1ror: Crystal Structures of The Catalytic Domain of Phosphodiesterase 4B2B Complexed with Amp
33. 3g58: Crystal Structure of Human Phosphodiesterase 4d with D155988/pmnpq
34. 3g4l: Crystal Structure of Human Phosphodiesterase 4d with Roflumilast
35. 3g4k: Crystal Structure of Human Phosphodiesterase 4d with Rolipram
36. 3g4i: Crystal Structure of Human Phosphodiesterase 4d with D155871
37. 3g4g: Crystal Structure of Human Phosphodiesterase 4d with Regulatory Domain and D155871
38. 3g45: Crystal Structure of Human Phosphodiesterase 4b with Regulatory Domain and D155988
39. 3g3n: PDE7A Catalytic Domain in Complex with 3-(2,6- Difluorophenyl)-2-(methylthio)quinazolin-4(3h)-one
40. 3frg: Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with a Quinoline Inhibitor
41. 1so2: Catalytic Domain of Human Phosphodiesterase 3b in Complex with a Dihydropyridazine Inhibitor
42. 1soj: Catalytic Domain of Human Phosphodiesterase 3b in Complex with Ibmx
43. 1t9r: Catalytic Domain of Human Phosphodiesterase 5a
44. 1t9s: Catalytic Domain of Human Phosphodiesterase 5a in Complex with Gmp
45. 1taz: Catalytic Domain of Human Phosphodiesterase 1b
46. 1tb5: Catalytic Domain of Human Phosphodiesterase 4b in Complex with Amp
47. 1tb7: Catalytic Domain of Human Phosphodiesterase 4d in Complex with Amp
48. 1tbb: Catalytic Domain of Human Phosphodiesterase 4d in Complex with Rolipram
49. 1tbf: Catalytic Domain of Human Phosphodiesterase 5a in Complex with Sildenafil
50. 3ecn: Crystal Structure of PDE8A Catalytic Domain in Complex with Ibmx
51. 3ecm: Crystal Structure of The Unliganded PDE8A Catalytic Domain
52. 1udt: Crystal Structure of Human Phosphodiesterase 5 Complexed with Sildenafil(viagra)
53. 1udu: Crystal Structure of Human Phosphodiesterase 5 Complexed with Tadalafil(cialis)
54. 1uho: Crystal Structure of Human Phosphodiesterase 5 Complexed with Vardenafil(levitra)
55. 3d3p: Crystal Structure of PDE4B Catalytic Domain in Complex with a Pyrazolopyridine Inhibitor
56. 2zmf: Crystal Structure of The C-terminal Gaf Domain of Human Phosphodiesterase 10a
57. 1xlx: Catalytic Domain of Human Phosphodiesterase 4b in Complex with Cilomilast
58. 1xlz: Catalytic Domain of Human Phosphodiesterase 4b in Complex with Filaminast
59. 1xm4: Catalytic Domain of Human Phosphodiesterase 4b in Complex with Piclamilast
60. 1xm6: Catalytic Domain of Human Phosphodiesterase 4b in Complex with (r)-mesopram
61. 1xmu: Catalytic Domain of Human Phosphodiesterase 4b in Complex with Roflumilast
62. 1xmy: Catalytic Domain of Human Phosphodiesterase 4b in Complex with (r)-rolipram
63. 1xn0: Catalytic Domain of Human Phosphodiesterase 4b in Complex with (r,s)-rolipram
64. 1xom: Catalytic Domain of Human Phosphodiesterase 4d in Complex with Cilomilast
65. 1xon: Catalytic Domain of Human Phosphodiesterase 4d in Complex with Piclamilast
66. 1xoq: Catalytic Domain of Human Phosphodiesterase 4d in Complex with Roflumilast
67. 1xor: Catalytic Domain of Human Phosphodiesterase 4d in Complex with Zardaverine
68. 1xos: Catalytic Domain of Human Phosphodiesterase 4b in Complex with Sildenafil
69. 1xot: Catalytic Domain of Human Phosphodiesterase 4b in Complex with Vardenafil
70. 1xoz: Catalytic Domain of Human Phosphodiesterase 5a in Complex with Tadalafil
71. 1xp0: Catalytic Domain of Human Phosphodiesterase 5a in Complex with Vardenafil
72. 1y2b: Catalytic Domain of Human Phosphodiesterase 4d in Complex with 3,5-dimethyl-1h-pyrazole-4-carboxylic Acid Ethyl Ester
73. 1y2c: Catalytic Domain of Human Phosphodiesterase 4d in Complex with 3,5-dimethyl-1-phenyl-1h-pyrazole-4-carboxylic Acid Ethyl Ester
74. 1y2d: Catalytic Domain of Human Phosphodiesterase 4d in Complex with 1-(4-methoxy-phenyl)-3,5-dimethyl-1h-pyrazole-4- Carboxylic Acid Ethyl Ester
75. 1y2e: Catalytic Domain of Human Phosphodiesterase 4d in Complex with 1-(4-amino-phenyl)-3,5-dimethyl-1h-pyrazole-4- Carboxylic Acid Ethyl Ester
76. 1y2h: Catalytic Domain of Human Phosphodiesterase 4b in Complex with 1-(2-chloro-phenyl)-3,5-dimethyl-1h-pyrazole-4- Carboxylic Acid Ethyl Ester
77. 1y2j: Catalytic Domain of Human Phosphodiesterase 4b in Complex with 3,5-dimethyl-1-(3-nitro-phenyl)-1h-pyrazole-4- Carboxylic Acid Ethyl Ester
78. 1y2k: Catalytic Domain of Human Phosphodiesterase 4d in Complex with 3,5-dimethyl-1-(3-nitro-phenyl)-1h-pyrazole-4- Carboxylic Acid Ethyl Ester
79. 2wey: Human Pde-papaverine Complex Obtained by Ligand Soaking of Cross-linked Protein Crystals
80. 1z1l: The Crystal Structure of The Phosphodiesterase 2a Catalytic Domain
81. 1zkl: Multiple Determinants for Inhibitor Selectivity of Cyclic Nucleotide Phosphodiesterases
82. 1zkn: Structure of PDE4D2-IBMX
83. 6zqz: [1,2,4]triazolo[1,5-a]pyrimidine Phosphodiesterase 2 Inhibitors
84. 6znd: [1,2,4]triazolo[1,5-a]pyrimidine Phosphodiesterase 2 Inhibitors
85. 2r8q: Structure of Lmjpdeb1 in Complex with Ibmx
86. 2qyn: Crystal Structure of PDE4D2 in Complex with Inhibitor Npv
87. 2chm: Crystal Structure of N2 Substituted Pyrazolo Pyrimidinones- a Flipped Binding Mode in Pde5
88. 2pw3: Structure of The PDE4D-CAMP Complex
89. 2ovy: Crystal Structure of The Catalytic Domain of Rat Phosphodiesterase 10a
90. 2ovv: Crystal Structure of The Catalytic Domain of Rat Phosphodiesterase 10a
91. 2ouy: Crystal Structure of PDE10A2 Mutant D564A in Complex with Camp.
92. 2ouv: Crystal Structure of PDE10A2 Mutant of D564N
93. 2ouu: Crystal Structure of PDE10A2 Mutant D674A in Complex with Cgmp
94. 2ous: Crystal Structure of PDE10A2 Mutant D674A
95. 2our: Crystal Structure of PDE10A2 Mutant D674A in Complex with Camp
96. 2ouq: Crystal Structure of PDE10A2 in Complex with Gmp
97. 2oup: Crystal Structure of PDE10A
98. 2oun: Crystal Structure of PDE10A2 in Complex with Amp
99. 2o8h: Crystal Structure of The Catalytic Domain of Rat Phosphodiesterase 10a
100. 6c7j: Crystal Structure of Human Phosphodiesterase 2a with 1-(5-tert-butoxy- 2-chloro-phenyl)-n-isobutyl-4-methyl-[1,2,4]triazolo[4,3- A]quinoxaline-8-carboxamide
101. 6c7i: Crystal Structure of Human Phosphodiesterase 2a with 1-(2-chloro-5- Methoxy-phenyl)-n-isobutyl-4-methyl-[1,2,4]triazolo[4,3- A]quinoxaline-8-carboxamide
102. 6c7g: Crystal Structure of Human Phosphodiesterase 2a with N-(1-adamantyl)- 1-(2-chloro-5-isobutoxy-phenyl)-4-methyl-[1,2,4]triazolo[4,3- A]quinoxaline-8-carboxamide
103. 6c7f: Crystal Structure of Human Phosphodiesterase 2a with 1-(2-chloro-5- Isobutoxy-phenyl)-n,4-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline-8- Carboxamide
104. 6c7e: Crystal Structure of Human Phosphodiesterase 2a with 1-(2- Chlorophenyl)-n,4-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline-8- Carboxamide
105. 6c7d: Crystal Structure of Human Phosphodiesterase 2a with N-(1-adamantyl)- 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8- Carboxamide
106. 6blf: Pde2 Complexed with 2-[6-fluoro-8-methylsulfonyl-9-[(1r)-1-[4- (trifluoromethyl)phenyl]ethyl]-1,2,3,4-tetrahydrocarbazol-1-yl]acetic Acid
107. 6b98: Pde2 in Complex with Compound 1
108. 6b97: Crystal Structure of Pde2 in Complex with Complex 9
109. 6b96: Crystal Structure of Pde2 in Complex with Compound 16
110. 5znl: Crystal Structure of PDE10A Catalytic Domain Complexed with Lhb-6
111. 2fm0: Crystal Structure of PDE4D in Complex with L-869298
112. 2fm5: Crystal Structure of PDE4D2 in Complex with Inhibitor L- 869299
113. 2hy1: Crystal Structure of Rv0805
114. 2hyo: Crystal Structure of Rv0805 N97A Mutant
115. 2hyp: Crystal Structure of Rv0805 D66A Mutant
116. 2ju4: Nmr Structure of The Gamma Subunit of Cgmp Phosphodiesterase
117. 6kze: The Crystal Structue of PDE10A Complexed with 4d
118. 2y0j: Triazoloquinazolines as a Novel Class of Phosphodiesterase 10a (PDE10A) Inhibitors, part 2, Lead-optimisation.
119. 6ko1: The Crystal Structue of PDE10A Complexed with 2d
120. 6ko0: The Crystal Structue of PDE10A Complexed with 1i
121. 3qpn: Structure of Pde10-inhibitor Complex
122. 3qpo: Structure of Pde10-inhibitor Complex
123. 3qpp: Structure of Pde10-inhibitor Complex
124. 3o56: Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with a 5- Heterocycle Pyrazolopyridine Inhibitor
125. 3o57: Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with a 5- Heterocycle Pyrazolopyridine Inhibitor
126. 3o0j: PDE4B in Complex with Ligand An2898
127. 3sl3: Crystal Structure of The Apo Form of The Catalytic Domain of PDE4D2
128. 3sl4: Crystal Structure of The Catalytic Domain of PDE4D2 with Compound 10d
129. 3sl5: Crystal Structure of The Catalytic Domain of PDE4D2 Complexed with Compound 10d
130. 3sl6: Crystal Structure of The Catalytic Domain of PDE4D2 with Compound 12c
131. 3sl8: Crystal Structure of The Catalytic Domain of PDE4D2 with Compound 10o
132. 3sn7: Highly Potent, Selective, and Orally Active Phosphodiestarase 10a Inhibitors
133. 3sni: Highly Potent, Selective, and Orally Active Phosphodiestarase 10a Inhibitors
134. 3snl: Highly Potent, Selective, and Orally Active Phosphodiestarase 10a Inhibitors
135. 3ui7: Discovery of Orally Active Pyrazoloquinoline as a Potent Pde10 Inhibitor for The Management of Schizophrenia
136. 3v9b: Crystal Structure of The Catalytic Domain of PDE4D2 with (s)-n-(3-{1- [1-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)-2-(1-oxypyridin-4- Yl)-ethyl]-1h-pyrazl-3-yl}phenyl)acetamide
137. 3tvx: The Structure of PDE4A with Pentoxifylline at 2.84a Resolution
138. 3uuo: The Discovery of Potent, Selectivity, and Orally Bioavailable Pyrozoloquinolines as Pde10 Inhibitors for The Treatment of Schizophrenia
139. 4ael: PDE10A in Complex with The Inhibitor Az5
140. 3v93: Unliganded Structure of Tcrpdec1 Catalytic Domain
141. 3v94: Tcrpdec1 Catalytic Domain in Complex with Inhibitor Wyq16
142. 4dff: The Sar Development of Dihydroimidazoisoquinoline Derivatives as Phosphodiesterase 10a Inhibitors for The Treatment of Schizophrenia
143. 4ddl: PDE10A Crystal Structure Complexed with Novel Inhibitor
144. 6msc: Novel, Potent, Selective and Brain Penetrant Phosphodiesterase 10a Inhibitors
145. 6msa: Novel, Potent, Selective and Brain Penetrant Phosphodiesterase 10a Inhibitors
146. 6ke0: Crystal Structure of PDE10A in Complex with a Triazolopyrimidine Inhibitor
147. 6kdz: Crystal Structure of PDE10A in Complex with a Triazolopyrimidine Inhibitor
148. 6kdx: Crystal Structure of PDE10A in Complex with a Triazolopyrimidine Inhibitor
149. 6k9u: Discovery of Pyrazolo[1,5-a]pyrimidine Derivative as a Highly Selective PDE10A Inhibitor
150. 4fcb: Potent and Selective Phosphodiesterase 10a Inhibitors
151. 4fcd: Potent and Selective Phosphodiesterase 10a Inhibitors
152. 6iji: Crystal Structure of Pde10 in Complex with Inhibitor 2b
153. 6ijh: Crystal Structure of Pde10 in Complex with Inhibitor Af-399/14387019
154. 4hf4: Crystal Structure of PDE10A with a Biaryl Ether Inhibitor (1-(1-(3-(4- (benzo[d]thiazol-2-ylamino)phenoxy)pyrazin-2-yl)piperidin-4-yl) Ethanol)
155. 4ajd: Identification and Structural Characterization of Pde10 Fragment Inhibitors
156. 4ajf: Identification and Structural Characterization of Pde10 Fragment Inhibitors
157. 4ajg: Identification and Structural Characterization of Pde10 Fragment Inhibitors
158. 4ajm: Development of a Plate-based Optical Biosensor Methodology to Identify Pde10 Fragment Inhibitors
159. 4jib: Crystal Structure of of Pde2-inhibitor Complex
160. 3w5e: Crystal Structure of Phosphodiesterase 4b in Complex with Compound 31e
161. 6ezf: Pde2 in Complex with Molecule 5
162. 4kp6: Crystal Structure of Human Phosphodiesterase 4b (PDE4B) in Complex with a [1,3,5]triazine Derivative
163. 6cyd: Pde2 in Complex with Compound 7
164. 6cyc: Pde2 in Complex with Compound 5
165. 6cyb: Pde2 in Complex with Compound 7
166. 3wd9: Crystal Structure of Phosphodiesterase 4b in Complex with Compound 10f
167. 3wi2: Crystal Structure of PDE10A in Complex with Inhibitor
168. 3ws8: Crystal Structure of PDE10A in Complex with a Benzimidazole Inhibitor
169. 3ws9: Crystal Structure of PDE10A in Complex with a Benzimdazole Inhibitor
170. 3wyk: Crystal Structure of The Catalytic Domain of PDE10A Complexed with 3- (1-phenyl-1h-pyrazol-5-yl)-1-(3-(trifluoromethyl)phenyl)pyridazin- 4(1h)-one
171. 3wyl: Crystal Structure of The Catalytic Domain of PDE10A Complexed with 5- Methoxy-3-(1-phenyl-1h-pyrazol-5-yl)-1-(3-(trifluoromethyl)phenyl) Pyridazin-4(1h)-one
172. 3wym: Crystal Structure of The Catalytic Domain of PDE10A Complexed with 1- (2-fluoro-4-(1h-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1h- Pyrazol-5-yl)pyridazin-4(1h)-one
173. 4bbx: Discovery of a Potent, Selective and Orally Active PDE10A Inhibitor for The Treatment of Schizophrenia
174. 4c1i: Selective Inhibitors of Pde2, Pde9, and Pde10: Modulators of Activity of The Central Nervous System
175. 4d08: PDE2A Catalytic Domain in Complex with a Brain Penetrant Inhibitor
176. 4d09: PDE2A Catalytic Domain in Complex with a Brain Penetrant Inhibitor
177. 4htx: Crystal Structure of Pde2 Catalytic Domain in Complex with Bay60-7550
178. 4htz: Crystal Structure of Pde2 Catalytic Domain in Space Group P1
179. 4lkq: Crystal Structure of PDE10A2 with Fragment Zt017
180. 4llj: Crystal Structure of PDE10A2 with Fragment Zt214
181. 4llk: Crystal Structure of PDE10A2 with Fragment Zt217
182. 4llp: Crystal Structure of PDE10A2 with Fragment Zt401
183. 4llx: Crystal Structure of PDE10A2 with Fragment Zt434
184. 4lm0: Crystal Structure of PDE10A2 with Fragment Zt448
185. 4lm1: Crystal Structure of PDE10A2 with Fragment Zt450
186. 4lm2: Crystal Structure of PDE10A2 with Fragment Zt462
187. 4lm3: Crystal Structure of PDE10A2 with Fragment Zt464
188. 4lm4: Crystal Structure of PDE10A2 with Fragment Zt902
189. 4mrw: Crystal Structure of PDE10A2 with Fragment Zt0120 (7-chloroquinolin-4- Ol)
190. 4mrz: Crystal Structure of PDE10A2 with Fragment Zt0429 (4-methyl-3- Nitropyridin-2-amine)
191. 4ms0: Crystal Structure of PDE10A2 with Fragment Zt0443 (6-chloropyrimidine- 2,4-diamine)
192. 4msa: Crystal Structure of PDE10A2 with Fragment Zt0449 (5-nitro-1h- Benzimidazole)
193. 4msc: Crystal Structure of PDE10A2 with Fragment Zt1595 (2-[(quinolin-7- Yloxy)methyl]quinoline)
194. 4mse: Crystal Structure of PDE10A2 with Fragment Zt1597 (2-({[(2s)-2-methyl- 2,3-dihydro-1,3-benzothiazol-5-yl]oxy}methyl)quinoline)
195. 4msh: Crystal Structure of PDE10A2 with Fragment Zt0143 ((2s)-4-chloro-2,3- Dihydro-1,3-benzothiazol-2-amine)
196. 4msn: Crystal Structure of PDE10A2 with Fragment Zt0451 (8-nitroquinoline)
197. 4muw: Crystal Structure of PDE10A with Novel Keto-benzimidazole Inhibitor
198. 4mvh: Crystal Structure of PDE10A with Novel Keto-benzimidazole Inhibitor
199. 4myq: Selective Inhibition of The Catalytic Domain of Human Phosphodiesterase 4b with A-33
200. 4npv: Crystal Structure of Human PDE1B Bound to Inhibitor 7a (6,7,8- Trimethoxy-n-(pentan-3-yl)quinazolin-4-amine)
201. 4npw: Crystal Structure of Human PDE1B Bound to Inhibitor 19a (7,8- Dimethoxy-n-[(2s)-1-(3-methyl-1h-pyrazol-5-yl)propan-2-yl]quinazolin- 4-amine)
202. 4nw7: Pde4 Catalytic Domain
203. 4p0n: Crystal Structure of PDE10A with a Novel Imidazo[4,5-b]pyridine Inhibitor
204. 4p1r: Crystal Structure of PDE10A with Imidazo[4,5-b]pyridines as Potent and Selective Inhibitors
205. 4phw: Crystal Structure of PDE10A with 1h-benzimidazol-2-yl(4-((3- (tetrahydro-2h-pyran-4-yl)-2-pyridinyl)oxy)phenyl)methanone
206. 5xuj: Crystal Structure of PDE10A in Complex with 7-(4-chlorophenyl)-2- Methylpyrazolo[1,5-a]pyrimidine
207. 5xui: Crystal Structure of PDE10A in Complex with 2-methyl-5-[2-([1,2, 4]triazolo[1,5-a]pyrimidin-2-yl)et Hyl]pyrazolo[1,5-a]pyrimidin-7-ol
208. 5xkm: Crystal Structure of Human Phosphodiesterase 2a in Complex with 6- Methyl-n-(1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5- A]pyrimidine-3-carboxamide
209. 5w6e: PDE1B Complexed with Compound 3s
210. 5vp1: Discovery of Clinical Candidate N-{(1s)-1-[3-fluoro-4- (trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3- Dihydropyrido[2,3-b]pyrazine-4(1h)-carboxamide (tak-915), a Highly Potent, Selective, and Brain-penetrating Phosphodiesterase 2a Inhibitor for The Treatment of Cognitive Disorders
211. 5vp0: Discovery of Clinical Candidate N-{(1s)-1-[3-fluoro-4- (trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3- Dihydropyrido[2,3-b]pyrazine-4(1h)-carboxamide (tak-915), a Highly Potent, Selective, and Brain-penetrating Phosphodiesterase 2a Inhibitor for The Treatment of Cognitive Disorders
212. 5uwf: Crystal Structure of Human PDE10A in Complex with Inhibitor 16d
213. 4ojv: Crystal Structure of Unliganded Yeast Pde1
214. 4ojx: Crystal Structure of Yeast Phosphodiesterase-1 in Complex with Gmp
215. 5up0: Crystal Structure of Human PDE1B Catalytic Domain in Complex with Inhibitor 3 (6-(4-chlorobenzyl)-8,9,10,11-tetrahydrobenzo[4, 5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6h)-one)
216. 5uoy: Crystal Structure of Human PDE1B Catalytic Domain in Complex with Inhibitor 16j (6-(4-methoxybenzyl)-9-((tetrahydro-2h-pyran-4-yl) Methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2, 4]triazolo[1,5-c]pyrimidin-5(6h)-one)
217. 5u7l: Pde2 Catalytic Domain Complexed with Inhibitors
218. 5u7k: Pde2 Catalytic Domain Complexed with Inhibitors
219. 5u7j: Pde2 Catalytic Domain Complexed with Inhibitors
220. 5u7i: Pde2 Catalytic Domain Complexed with Inhibitors
221. 5u7d: Pde2 Catalytic Domain Complexed with Inhibitors
222. 5u00: Crystal Structure of Human Phosphodiesterase 2a in Complex with 3,3- Difluoro-1-[(4-fluoro-3-iodophenyl)carbonyl]-5-{5-methyl-[1,2, 4]triazolo[1,5-a]pyrimidin-7-yl}piperidine
223. 5tzz: Crystal Structure of Human Phosphodiesterase 2a in Complex with 1-[(3- Bromo-4-fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2, 4]triazolo[1,5-a]pyrimidin-7-yl}piperidine
224. 5tzx: Crystal Structure of Human Phosphodiesterase 2a in Complex with 1-[(3- Chloro-4-fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2, 4]triazolo[1,5-a]pyrimidin-7-yl}piperidine
225. 5tzw: Crystal Structure of Human Phosphodiesterase 2a in Complex with 1-[(3, 4-difluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2, 4]triazolo[1,5-a]pyrimidin-7-yl}piperidine
226. 5tzh: Crystal Structure of Human Phosphodiesterase 2a in Complex with 3,3- Difluoro-1-[(4-fluorophenyl)carbonyl]-5-{5-methyl-[1,2,4]triazolo[1, 5-a]pyrimidin-7-yl}piperidine
227. 5tzc: Crystal Structure of Human PDE2A in Complex with (5s)-1-[(3-bromo-4- Fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5- A]pyrimidin-7-yl}piperidine
228. 5tza: Crystal Structure of Human Phosphodiesterase 2a with 3-{5-methyl-[1,2, 4]triazolo[1,5-a]pyrimidin-7-yl-1-[(naphthalene-2-yl) Carbonyl]piperidine
229. 5tz3: Crystal Structure of Human Phosphodiesterase 2a in Complex with [1,2, 4]triazolo[1,5-a]pyrimidin-7-yl}-n-(naphthalene-2-yl)piperidine-3- Carboxamide
230. 5k9r: PDE10A with Imidazopyrazine Inhibitor
231. 5i2r: Human PDE10A in Complex with 3-(2-phenylpyrazol-3-yl)-1-[3- (trifluoromethoxy)phenyl]pyridazin-4-one
232. 5edi: Human PDE10A, 6-chloro-5,8-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl- 2h-[1,2,4]triazol-3-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine, 2.20a, H3, Rfree=23.5%
233. 5edh: Human PDE10A, 8-ethyl-5-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4- Triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine, 2.03a, H3, Rfree=22.7%
234. 5edg: Human PDE10A in Complex with 3-(2-chloro-5-phenyl-3h-imidazol-4-yl)-1- (3-trifluoromethoxy-phenyl)-1h-pyridazin-4-one at 2.30a
235. 5ede: Human PDE10A in Complex with 1-(4-chloro-phenyl)-3-methyl-1h-thieno[2, 3-c]pyrazole-5-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide at 2.2a
236. 5dh5: Pde10 Complexed with N-[(1-methylpyrazol-4-yl)methyl]-5-[[(1s,2s)-2- (2-pyridyl)cyclopropyl]methoxy]pyrazolo[1,5-a]pyrimidin-7-amine
237. 5dh4: Pde10 Complexed with 5-chloro-n-[(2,4-dimethylthiazol-5-yl) Methyl]pyrazolo[1,5-a]pyrimidin-7-amine
238. 5c2h: Pde10 Complexed with 6-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]-5- Methyl-2-[3-(2-quinolyl)propoxy]pyrimidin-4-amine
239. 5c2e: Pde10 Complexed With6-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]-5- Methyl-2-[2-(2-pyridyl)ethoxy]pyrimidin-4-amine
240. 5c2a: Pde10 Complexed with 6-chloro-2-cyclopropyl-n-[(2,4-dimethylthiazol-5- Yl)methyl]-5-methyl-pyrimidin-4-amine
241. 5c29: Pde10 Complexed with 6-chloro-2-cyclopropyl-5-methyl-n-propyl- Pyrimidin-4-amine
242. 5c28: Pde10 Complexed with 6-chloro-2-cyclopropyl-5-methyl-pyrimidin-4-amine
243. 5c1w: Pde10 Complexed with 4,6-dichloro-2-cyclopropyl-5-methyl-pyrimidine
244. 4tpm: Crystal Structure of 2-(3-alkoxy-1-azetidinyl) Quinolines as PDE10A Inhibitors
245. 4tpp: 2-(3-alkoxy-1-azetidinyl) Quinolines as Novel PDE10A Inhibitors
246. 5b4l: Crystal Structure of The Catalytic Domain of Human PDE10A Complexed with 1-(cyclopropylmethyl)-5-(2-(2,3-dihydro-1h-imidazo[1,2- A]benzimidazol-1-yl)ethoxy)-3-(1-phenyl-1h-pyrazol-5-yl)pyridazin- 4(1h)-one
247. 5b4k: Crystal Structure of The Catalytic Domain of Human PDE10A Complexed with N-(4-((5-methyl-5h-pyrrolo[3,2-d]pyrimidin-4-yl)oxy)phenyl)-1h- Benzimidazol-2-amine
248. 5b25: Crystal Structure of Human PDE1B with Inhibitor 3
249. 5axq: Crystal Structure of The Catalytic Domain of PDE10A Complexed with Highly Potent and Brain-penetrant PDE10A Inhibitor with 2-oxindole Scaffold
250. 5axp: Crystal Structure of The Catalytic Domain of PDE10A Complexed with 1- (2-fluoro-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl)-5-methoxy-3-(1-phenyl- 1h-pyrazol-5-yl)pyridazin-4(1h)-one
251. 4wn1: Crystal Structure of PDE10A in Complex with 1-methyl-5-(1-methyl-3- {[4-(quinolin-2-yl)phenoxy]methyl}-1h-pyrazol-4-yl)pyridin-2(1h)-one
252. 4zo5: Pde10 Complexed with 4-isopropoxy-2-(2-(3-(4-methoxyphenyl)-4-oxo-3,4- Dihydroquinazolin-2-yl)ethyl)isoindoline-1,3-dione
253. 4yqh: 2-[2-(4-phenyl-1h-imidazol-2-yl)ethyl]quinoxaline (sunovion Compound 14) Co-crystallized with PDE10A
254. 4ys7: Co-crystal Structure of 2-[2-(5,8-dimethyl[1,2,4]triazolo[1,5- A]pyrazin-2-yl)ethyl]-3-methyl-3h-imidazo[4,5-f]quinoline (compound 39) with PDE10A
255. 4xy2: Crystal Structure of PDE10A in Complex with Asp9436
256. 7bpi: The Crystal Structue of PDE10A Complexed with 14
257. 7lrc: Cryo-em of The SLFN12-PDE3A Complex: PDE3A Body Refinement
258. 7lrd: Cryo-em of The SLFN12-PDE3A Complex: Consensus Subset Model
259. 7kwe: Crystal Structure of The Catalytic Domain of Human PDE3A Bound to Dnmdp
260. 7l27: Crystal Structure of The Catalytic Domain of Human PDE3A
261. 7l28: Crystal Structure of The Catalytic Domain of Human PDE3A Bound to Trequinsin
262. 7l29: Crystal Structure of The Catalytic Domain of Human PDE3A Bound to Amp
263. 7eg0: Cryo-em Structure of Anagrelide-induced PDE3A-SLFN12 Complex
264. 7eg4: Cryo-em Structure of Nauclefine-induced PDE3A-SLFN12 Complex
265. 7eg1: Cryo-em Structure of Dnmdp-induced PDE3A-SLFN12 Complex